1Salmon JM,Kilpatrick SE.Pathology of skeletal metastases [J].Orthop Clin North Am,2000,31(4):537～544.
2Clain A.Secondary malignant disease of bone [J].Br J Cancer,1965,19:15～29.
3Delmas PD,5 Schlemmer A,Gineyts E,et al.Urinary excretion of pyridinoline cross-links correlate with bone turn over measured on iliocrsest bone biopsy in patients with vertebral osteoporosis[J].J Bone Miner Res,1991,6(1):639～644.
4JJ.Body.Metastic Bone Disease:Clinical and Therapeutic Aspects.Bone,1992,3,S57-S62Paterson AHG.Bone metastases in breast cancer,prostate cancer and myeloma[J].Bone,1987,8(suppl 1):17～22.
5Coleman RE,Mashiter G,Whitaker KB,et al.Bone scan flare predict successful systemic therapy for bone metastases [J].Med J Nucl,1988,29(8):1354～1359.
6Lipton A,Costa L,Ail S,et al.Use of Bone Turnover for Monitoring Bone Metastases and the Respone to Therapy [J].Semin Oncol,2001,28(4 Suppl 11):54～59.
7Miyamoto KK,McSherry SA,Robins SP,et al.Collagen crosslink metabolites in urine as markers of bone metastases in prostatic carcinoma[J].J Urol,1994,151(4):909～913.
8Demers LM,Costa L,Chinchilli VM,et al.Biochemical markers of bone turnover in patients with metastatic bone disease[J].GlinChem,1995,41(10):1489～1494.
9Berruti A,Dogliotti L,Gorzegno G,et al.Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases[J].Clin Chem,1999,45(8):1240～1247.
10Niwa T,Shiobara K,Hamada T,et al.Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients [J].Clin ChimActa,1995,235(1):33～40.
